Art. 5 Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 20…

In forcesince 28 Jan 2019cited 36×
1.

A Committee for Medicinal Products for Human Use is hereby established. The Committee shall be part of the Agency.

2.

Without prejudice to Article 56 or to other tasks which Union law may confer on it, the Committee for Medicinal Products for Human Use shall be responsible for drawing up the opinion of the Agency on any matter concerning the admissibility of the files submitted in accordance with the centralised procedure, the granting, variation, suspension or revocation of an authorisation to place a medicinal product for human use on the market in accordance with the provisions of this Title, and pharmacovigilance. For the fulfilment of its pharmacovigilance tasks, including the approval of risk management systems and monitoring their effectiveness provided for under this Regulation, the Committee for Medicinal Products for Human Use shall rely on the scientific assessment and recommendations of the Pharmacovigilance Risk Assessment Committee referred to in Article 56(1)(aa).

3.

At the request of the Executive Director of the Agency or the Commission representative, the Committee for Medicinal Products for Human Use shall also draw up an opinion on any scientific matter concerning the evaluation of medicinal products for human use. The Committee shall take due account of any requests by Member States for an opinion. The Committee shall also formulate an opinion whenever there is disagreement in the evaluation of medicinal products through the mutual recognition procedure. The opinion of the Committee shall be made publicly accessible.

The 10 that are cited most themselves, of 36.

  • Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 Decembe…283138Law

    … продукти, предназначени за хуманна употреба на основание член 5, параграф 3 и член 57, параграф 1, буква п) от Регламент (ЕО) № 726/2004 от 31 …

  • Regulation (EC) No 1394/2007 of the European Parliament and of the Council of 13 Novembe…8Law

    … е необходимо за изготвяне на научните становища, посочени в член 5, параграфи 2 и 3 от Регламент (ЕО) № 726/2004. Комитетът за модерни …

  • Arrêt du Tribunal (septième chambre) du 11 juin 2015. Laboratoires CTRS contre Commission européenne.Decision

    … of Regulation No 1901/2006 provides: ‘Applications may be submitted in accordance with the procedure laid down in Articles 5 to 15 of Regulation (EC) No 726/2004 for a marketing authorisation as referred to in Article 7(1) of this …

    11 Jun 2015 · 62014TJ0452

  • Judgment of the General Court (Sixth Chamber) of 19 December 2019. Vanda Pharmaceuticals Ltd v European Commission.Decision

    In the evaluation process, ‘exclusive responsibility’ for preparing EMA opinions on all matters relating to medicinal products for human use is vested in the CHMP (see recital 23 and Article 5(2) of Regulation No 726/2004). …

    19 Dec 2019 · 62018TJ0211

  • Judgment of the General Court (Seventh Chamber, Extended Composition) of 5 May 2021. Pharmaceutical Works Polpharma S.A. v European MedicineDecision

    On 21 July 2011, the Committee for Medicinal Products for Human Use (‘the CHMP’), established by Article 5(1) of Regulation No 726/2004, considered that Biogen Idec’s product, containing DMF, was eligible for submission of an …

    5 May 2021 · 62018TJ0611

  • Judgment of the Court (Fourth Chamber) of 16 March 2023. European Commission and Others v Pharmaceutical Works Polpharma S.A.Decision

    Article 5(1) of that regulation states: ‘A Committee for Medicinal Products for Human Use is hereby established. The Committee shall be part of the [EMA].’

    16 Mar 2023 · 62021CJ0438

  • Arrêt du Tribunal (huitième chambre) du 2 mars 2022. Debregeas et associés Pharma (D & A Pharma) contre Commission européenne et Agence euroDecision

    S’agissant de l’avis de l’EMA, il résulte du considérant 23 et de l’article 5, paragraphe 2, du règlement n o 726/2004 que la « responsabilité exclusive » de sa préparation est confiée au CHMP, institué par l’article 121 …

    2 Mar 2022 · 62020TJ0556

  • Judgment of the General Court (Sixth Chamber) of 28 October 2020. Pharma Mar, SA v European Commission.Decision

    As regards the EMA’s opinion, it is clear from recital 23 and Article 5(2) of Regulation No 726/2004 that ‘exclusive responsibility’ for preparing it is conferred on the CHMP.

    28 Oct 2020 · 62018TJ0594

  • The Human Medicines Regulations 20128Law

    … its usual common name; “the Committee for Medicinal Products for Human Use” means the committee established under Article 5(1) of Regulation (EC) No 726/2004; “conditional marketing authorisation” means a UKMA(UK)(Category 1) …

  • The Human Medicines (Amendment etc.) (EU Exit) Regulations 2019610Law

    … the 2001 Directive; ; “the Committee for Medicinal Products for Human Use” means the committee established under Article 5(1) of Regulation (EC) No 726/2004; ; “the EMA” means the European Medicines Agency established by Regulation …